We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Tests to Assess Risk of Hereditary Colon Cancer

By HospiMedica staff writers
Posted on 29 May 2002
Tests have been developed that detect genetic mutations predictive of hereditary colon cancer. More...
One test detects mutations in the APC gene, which causes familial adenomatous polyposis (FAP), a hereditary form of colon cancer that may cause up to 20% of hereditary disease. A second test identifies mutations unassociated with polyp formation.

The test that detects APC mutations is called Colaris AP, and this test also detects a more common variation of FAP known as attenuated FAP (aFAP), which may account for 20% of all colon cancer cases. The second test, for hereditary cancer unassociated with polyp formation, is called Colaris. Together, the two tests may detect about 90% of all hereditary colon cancer, states the developer, Myriad Genetics, Inc. (Salt Lake City, UT, USA). Each test provides a full-sequence DNA analysis to detect genetic mutations. Early detection may prevent the spread of colon cancer.

The average age at diagnosis of colon cancer among FAP patients is 35. Myriad advises that in addition to direct testing for Colaris AP, people with a family history of colon cancer who are negative on this test should consider adding the Colaris test to rule out the other major hereditary colon cancer syndrome. The company has introduced an accelerated turnaround version of Colaris, called Rapid Colaris. This version is designed to help doctors determine the best procedure for patients awaiting surgery following a diagnosis of colon cancer.

"Colaris AP extends our existing franchise with oncologists and cancer centers, providing a one-stop shop for hereditary colon cancer prediction and diagnosis,” said Gregory Critchfield, M.D., president of Myriad Genetic Laboratories, Inc.




Related Links:
Myriad

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Monitor/Defibrillator
Zenix
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.